Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H1ssF-3928 mRNA-LNP
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H1ssF-3928 mRNA-LNP is an experimental universal influenza vaccine candidate developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This vaccine utilizes a messenger RNA (mRNA) platform delivered via lipid nanoparticles (LNP). Its mechanism of action involves instructing the body's cells to produce the stable stem region of the influenza virus's hemagglutinin (HA) protein. By targeting this highly conserved stem region, which mutates less frequently than the HA head, the vaccine aims to induce a broad and durable immune response against a wide range of influenza strains. This approach is intended to provide long-lasting protection, potentially eliminating the need for annual seasonal flu vaccinations and offering a defense against future influenza pandemics.
- Other names
- universal influenza vaccine candidate
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on H1ssF-3928 mRNA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H1ssF-3928 mRNA-LNP.